Experienced in Hereditary Neuralgic Amyotrophy

Thomas Hundsberger

Cantonal Hospital St. Gallen
Sankt Gallen, SG, CH 
Experienced in Hereditary Neuralgic Amyotrophy
Cantonal Hospital St. Gallen
Sankt Gallen, SG, CH 
OverviewLocationsClinical Research

Overview

Thomas Hundsberger practices in Sankt Gallen, Switzerland. Mr. Hundsberger is rated as an Experienced expert by MediFind in the treatment of Hereditary Neuralgic Amyotrophy. His top areas of expertise are Pompe Disease, Glioblastoma, Astrocytoma, and Glioma.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hereditary Neuralgic Amyotrophy.

Gender
Male

Locations

Cantonal Hospital St. Gallen
Sankt Gallen, SG 9000, Switzerland
Other Locations
Cantonal Hospital St Gallen, St Gallen
Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
View 1 Less Clinical Trial

81 Total Publications

First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.
First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland.
Journal: Current oncology (Toronto, Ont.)
Published: December 22, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hundsberger's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile